Home › Funds › SCHOLTZ & COMPANY, LLC › ABT
SCHOLTZ & COMPANY, LLC position in ABT
ABBOTT LABORATORIES · Health Care
SCHOLTZ & COMPANY, LLC reported holding 21,694 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$2.1M, representing 1.13% of its reported portfolio and ranking #32 among its reported holdings. SCHOLTZ & COMPANY, LLC has disclosed ABT holdings in 12 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SCHOLTZ & COMPANY, LLC's ABT position evolved
SCHOLTZ & COMPANY, LLC first disclosed a stake in ABT in Q3 2023 at 34,633 shares (US$3.4M). The position peaked in Q3 2025 at 48,047 shares, worth US$6.4M. Across 12 filings, SCHOLTZ & COMPANY, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 21,694 shares valued at US$2.1M. Notable position changes include a 57% trim in Q4 2023 (shares rose 4% over the following quarter), a 53% trim in Q1 2024 (shares fell 8% over the following quarter), a 478% increase in Q2 2024 (shares rose 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 34.63K | $3.35M | New |
| Q4 2023 | 14.92K | $1.64M | Reduce |
| Q1 2024 | 7.03K | $799.26K | Reduce |
| Q2 2024 | 40.66K | $4.22M | Add |
| Q3 2024 | 41.56K | $4.74M | Add |
| Q4 2024 | 47.46K | $5.37M | Add |
| Q1 2025 | 47.37K | $6.28M | Hold |
| Q2 2025 | 46.63K | $6.34M | Reduce |
| Q3 2025 | 48.05K | $6.44M | Add |
| Q4 2025 | 49.20K | $6.16M | Add |
| Q1 2026 | 43.88K | $4.50M | Reduce |
| Q3 2026 | 21.69K | $2.14M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 44.98M sh · $4.45B · Q3 2026
- Capital International Investors 35.46M sh · $3.51B · Q3 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Franklin Resources 20.44M sh · $2.36B · Q3 2026
- Deutsche Bank AG 17.69M sh · $1.75B · Q3 2026
- MFS Investment Management 14.93M sh · $1.48B · Q3 2026
More on SCHOLTZ & COMPANY, LLC
FAQ
How long has SCHOLTZ & COMPANY, LLC held ABT?
SCHOLTZ & COMPANY, LLC has disclosed ABT holdings in 12 of the last 13 reported quarters, going back to Q3 2023.
What is SCHOLTZ & COMPANY, LLC's current position in ABT?
As of Q3 2026, SCHOLTZ & COMPANY, LLC holds 21.69K shares of ABT (ABBOTT LABORATORIES), valued at $2.14M, representing 1.13% of its reported portfolio and ranking #32.
Has SCHOLTZ & COMPANY, LLC been buying or selling ABT?
In the latest 13F filing (Q3 2026), SCHOLTZ & COMPANY, LLC newly opened its position in ABT. The position peaked in Q3 2025 at 48.05K shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.